Lung disease is the major cause of morbidity and mortality in cystic fibrosis, an autosomal recessive disease caused by mutations in CFTR. In cystic fibrosis, chronic infection and dysregulated neutrophilic inflammation lead to progressive airway destruction. The severity of cystic fibrosis lung disease has considerable heritability, independent of CFTR genotype 1 . To identify genetic modifiers, here we performed a genome-wide single nucleotide polymorphism scan in one cohort of cystic fibrosis patients, replicating top candidates in an independent cohort. This approach identified IFRD1 as a modifier of cystic fibrosis lung disease severity. IFRD1 is a histone-deacetylase-dependent transcriptional co-regulator expressed during terminal neutrophil differentiation. Neutrophils, but not macrophages, from Ifrd1deficient mice showed blunted effector function, associated with decreased NF-kB p65 transactivation. In vivo, IFRD1 deficiency caused delayed bacterial clearance from the airway, but also less inflammation and disease-a phenotype primarily dependent on haematopoietic cell expression, or lack of expression, of IFRD1. In humans, IFRD1 polymorphisms were significantly associated with variation in neutrophil effector function. These data indicate that IFRD1 modulates the pathogenesis of cystic fibrosis lung disease through the regulation of neutrophil effector function.
Attention to the role of CFTR in regulating epithelial ion transport has failed to illuminate the path from gene to pathogenesis in cystic fibrosis (CF) lung disease. In CF, colonization and infection (paradigmatically with Pseudomonas aeruginosa) is associated with neutrophilic inflammation, the end result being progressive airway destruction 2 . This inflammatory response is out of proportion to inciting infectious stimuli 3 , which may well be due to the compromise of lipid mediator pathways driving resolution of neutrophilic inflammation 4 .
To identify genetic modifiers of CF lung disease severity, we performed a genome-wide single nucleotide polymorphism (SNP) scan in the Genetic Modifier Study Group (GMSG) cohort, followed by validation of top candidates in the US CF Twin and Sib Study (CFTSS) cohort. The former enrolled DF508 CFTR homozygotes with extremes of lung function for age, for case-control association approaches to modifier gene identification 5 . The latter enrolled CFaffected twins and siblings with any CFTR genotype, and their parents, for transmission-based approaches 1 . Severity status was quantified using lung function measures highly correlated with survival in CF 6 .
Genome-wide SNP analysis was performed using Affymetrix 100K microarrays in 320 patients from the GMSG cohort 5 : 160 with severe and 160 with mild lung disease, with DNA from 20 subjects pooled per microarray. To assess the robustness of the pooling approach, we first compared gene chip estimates of allele frequencies in pooled samples with individually genotyped frequencies in a subset of 93 SNPs. A high degree of correlation (r 2 5 0.88) was found. Second, the comparison of genome-wide allele frequencies in these CF patients with those from a similar pooled genome-wide scan in asthma patients and controls (from an Isle of Wight birth cohort study 7 ) unambiguously identified CFTR as the disease-causing locus in CF. Of the top-ranked polymorphisms distinguishing the two cohorts, in terms of statistically significant differences in allele frequency, 34 out of 38 were clustered on chromosome 7, centred around CFTR, with a median uncorrected P value of 3 3 10 28 ( Supplementary Fig. 1 ). Several of these SNPs would not pass Bonferroni correction for multiple testing, given the .100K SNPs on the microarrays-despite the known biological significance of CFTR. Thus, in addition to generating false positive results, correction for multiple testing in genomewide SNP scans can also generate false negative results.
To differentiate true from false association (or false lack of association), we prioritized follow-up efforts according to hierarchical criteria, focusing, first on regional clusters of SNPs exhibiting different allele frequencies ( Supplementary Fig. 2 ), and second on regions containing genes with biological coherence: regulators of transcription, genes with known function in the immune system or in lung biology, and genes implicated in biological functions that are abnormal in the CF airway (for example, ion channels). The latter criterion was unlikely to facilitate the identification of genes with unknown function or of unexpected pathogenetic pathways. However, we aimed to identify true modifiers among false positives, not to identify all modifiers. This heuristic approach was used to select 6 regions/genes for followup study: IFRD1, CEBPA/CEBPG, CHI3L2, C6, SLC4A3 and ABCA1.
The top-ranked locus in terms of clustering was IFRD1, 5 megabases (Mb) away from CFTR, the 39 region of which contained a cluster of nine SNPs (Supplementary Table 1 and Supplementary Fig. 2b ) with significantly different allele frequencies between patient groups. Biology is addressed later. To confirm the genotyping in the pooled scan, as well as define which SNPs to pick for replication purposes, SNPs in IFRD1 reaching significance in the pooling experiment, along with tagging SNPs throughout and flanking the region of the effect, were individually genotyped in the wider GMSG cohort. Although no association signal was observed for IFRD1-flanking markers, retention of association signal for a cluster of SNPs on the haplotype block containing the 39 IFRD1 exons (Supplementary Tables 2, 3 and Supplementary Fig. 3 ) led us to pursue replication in a separate population.
Three IFRD1 SNPs (rs7817, rs3807213 and rs6968084) that linkage disequilibrium analysis suggested captured the bulk of the variation observed at this locus were genotyped in patients in the CFTSS cohort ( Supplementary Table 4 ). Notably, the family-based association test demonstrated significant association between the rs7817 polymorphism and both cross-sectional and longitudinal measures of lung function (Table 1a ). The other two SNPs showed trends towards significance (rs3807213, P 5 0.080; rs6968084, P 5 0.082; for longitudinal and cross-sectional measures of lung function, respectively). A second, complementary method (quantitative transmission disequilibrium test) verified the result derived for rs7817 (Table 1b) . Notably, both methods showed that the heterozygote genotype ('CT') was associated with lower lung function than either homozygote ('CC' or 'TT'; data not shown). However, other genotype models (additive, recessive and dominant) could not be conclusively excluded. It was important to exclude linkage with CFTR alleles as the cause of the observed association between IFRD1 SNPs and CF lung function. No correlation was detected between genotypes composed of IFRD1 SNPs and the presence of 0, 1 or 2 copies of the common mutation DF508, or when CFTR mutations were grouped according to their association with exocrine pancreatic status. Furthermore, there was no evidence of linkage between the SNPs and the pulmonary phenotypes 8 , important for validating the association model used (a test of association in the absence, as opposed to the presence, of linkage). These data indicate that IFRD1 polymorphisms contribute to lung function variation in CF independent of CFTR.
IFRD1 acts in a histone deacetylase (HDAC)-dependent manner to mediate transcriptional co-repression and co-activation 9 . Expression and genetic deletion studies have implicated IFRD1 in cell differentiation and stress responses 10 . Available databases suggested highest expression in human blood cells 11 . Flow cytometric analysis of such cells demonstrated greatest expression in neutrophils ( Supplementary Fig.  4a ). Similarly, quantitative PCR with reverse transcription (qRT-PCR) analysis of cells relevant to the CF airway indicated particular enrichment of expression in neutrophils ( Supplementary Fig. 4b ). Terminal differentiation of human and mouse neutrophils was associated with robust upregulation of IFRD1 expression ( Supplementary Fig. 5 ), something that was mirrored in expression databases 12 . Neutrophilic differentiation of HL-60 cells also led to upregulation of IFRD1 expression ( Supplementary Fig. 6a ), and short interfering RNA (siRNA)-mediated knockdown of IFRD1 in such cells blunted oxidative burst capacity ( Supplementary Fig. 6b , c) without altering visual morphology or the surface expression of CD11b (encoded by ITGAM) (data not shown).
No alteration in peripheral blood neutrophil count, morphology, or CD11b and Gr-1 (encoded by Ly6g) expression were observed in Ifrd1 2/2 mice 13 (data not shown). However, neutrophils from Ifrd1 2/2 mice showed significant impairment of specific effector functions-including oxidative burst, bacterial killing, TNF-a, KC (CXCL1) and leukotriene B 4 (LTB 4 ) production, but not chemotaxis-compared with wild type and/or heterozygote littermate controls ( Fig. 1) . In vivo stimulation led to similar results: after intratracheal lipopolysaccharide (LPS) stimulation, Ifrd1 2/2 mice exhibited significantly less TNF-a production on a per cell basis in neutrophils, but not macrophages, compared with wild-type controls (data not shown). No differences in airway neutrophil numbers or apoptosis were seen in these studies (data not shown). These functional effects showed specificity among myeloid cells; peritoneal macrophages from Ifrd1 2/2 mice showed normal oxidative burst capacity and LPS-driven TNF-a production ( Supplementary Fig. 7 ). Thus, IFRD1 has an important role in the regulation of neutrophil effector function.
We subsequently analysed the role of IFRD1 in modulating airway infection with P. aeruginosa. Genetic deficiency of Ifrd1 was associated with significantly slower bacterial clearance ( Fig. 2a) . Notably, however, Ifrd1 2/2 mice also had significantly ameliorated disease, with less weight loss, and less airway and systemic inflammation ( Fig. 2b-f ). To define whether this was due to haematopoietic cell IFRD1 expression, C57BL/6 (CD45.1) mice were lethally irradiated and reconstituted with bone marrow cells from CD45.2-expressing wild-type or Ifrd1 2/2 mice. No differences in bone marrow reconstitution efficiency were observed ( Supplementary Fig. 8a ). Indeed, competitive reconstitution assays formally demonstrated the lack of a role for IFRD1 in early neutrophil development ( Supplementary Fig. 8b ). Wild-type mice reconstituted with IFRD1-deficient bone marrow cells mirrored the phenotype of Ifrd1 2/2 mice during P. aeruginosa infection-with less efficient bacterial clearance, but less inflammation and disease ( Supplementary Fig. 9 ). When reciprocal bone marrow transfers were performed (reconstituting lethally irradiated CD45.2-expressing wild type and Ifrd1 2/2 mice with bone marrow cells from wild-type C57BL/ 6 (CD45.1) mice), no such differences in bacterial burden, inflammation or disease course were seen ( Supplementary Fig. 10 ). Thus, IFRD1 modulation of the airway response to P. aeruginosa infection is largely dependent on haematopoietic cell expression of IFRD1.
Airway challenge with LPS was similarly associated with increased TNF-a and KC in bronchoalveolar lavage (BAL) fluid from wild-type, compared with Ifrd1 2/2 , mice ( Supplementary Fig. 11a, b) . In vivo HDAC inhibition blunted LPS-driven airway TNF-a and KC production, specifically in wild-type, but not in Ifrd1 2/2 , mice ( Supplementary Fig. 11a, b ). Furthermore, bone marrow transfer experiments showed that the effects of HDAC inhibition on LPSdriven airway TNF-a production-in BAL and by airway neutrophils ( Supplementary Fig. 11c, d) , but not by airway macrophages (data not shown)-was dependent on haematopoietic cell IFRD1 expression.
The effector functions blunted in the absence of IFRD1 are dependent on NF-kB p65 (also known as RelA) 14, 15 . Ifrd1 2/2 mice showed significantly decreased LPS-stimulated neutrophil NF-kB p65 transactivation, compared with littermate controls ( Supplementary Fig. 12a ). As IFRD1, NF-kB p65 and HDAC1 were co-immunoprecipitable in neutrophil nuclear extracts ( Supplementary Fig. 12b ), it seems probable that IFRD1 mediates its effects on neutrophils, at least in part, by direct interactions with NF-kB. Although our data are compatible with IFRD1 being a co-activator of transcriptional activity or a co-repressor of an inhibitor of transcriptional activity, the HDAC inhibition experiments suggest the latter. Co-immunoprecipitation analysis suggests the possibility of HDAC-mediated co-repression of an NF-kB-driven transcriptional inhibitor of NF-kB transactivation.
Although we may have not identified the causal variant(s) 16 , cogent hypotheses exist for how the identified SNPs may alter IFRD1 expression and/or function (Supplementary Discussion). To test directly the association of IFRD1 polymorphisms with neutrophil effector function, we studied neutrophils from healthy subjects. Notably, analysis of human peripheral blood neutrophils showed a significant association of IFRD1 polymorphisms with quantitative measures of neutrophil effector function (Fig. 3) . Taken together, these data suggest that IFRD1 modulates the course of CF airway disease through the regulation of neutrophil effector function.
Biology is rarely simple, however. The predictive value of mouse knockout models for the more subtle biological differences that probably result from human allelic polymorphisms, as well as the power of the functional data from human neutrophils to account for the effects of these polymorphisms on lung function over time, should not be overstated. It remains possible that neutrophils are not the only cells influenced by IFRD1 polymorphisms in a fashion relevant to cystic fibrosis. There may, for example, be ways in which respiratory epithelia and neutrophils interact through IFRD1 polymorphisms to modulate cystic fibrosis lung disease. On the whole, Cftr knockout and mutant mouse models have been disappointing; despite recapitulation of gut pathology, pulmonary phenotypes have been subtle. Whether this relates to different lung architecture in mice and humans, the influence of other genes in the mouse strains used, or stronger baseline immune counter-regulation in the mouse lung remains unclear. There is thus an essential problem with using LETTERS such models to define whether the absence of Ifrd1 (or the presence of mutant Ifrd1 alleles) ameliorates CF lung disease, in the absence of a robust phenotype to ameliorate. In this light, the recent report of pigs with targeted disruption of CFTR 17 may point the way to informative models.
Of the other top-ranked genes/regions from the initial scan, C6, SLC4A3 and ABCA1 did not survive genotyping in the wider GMSG cohort; CHI3L2 failed replication in the CFTSS cohort (data not shown). However, after refinement of the association signal from the pooled scan in the locus containing CEBPA and CEBPG (Supplementary Table 5 ) via individual genotyping in the wider GMSG cohort ( Supplementary  Tables 6 and 7) , replication was pursued in the CFTSS cohort. As shown in Supplementary Table 8 , polymorphisms in the 40 kb intergenic region between CEBPA and CEBPG (genes oriented 59 to each other) were significantly associated with variation in CF lung function. Although there are clearly other possible ways in which these transcription factors may affect CF lung disease severity 18, 19 , CEBPa is essential for neutrophil development 20 , a pathway that CEBPc has also been implicated in 21 .
Despite considerable progress in CF therapy over recent decades, the norm is still an inexorable decline in pulmonary function. The identification of genes modifying CF lung disease, and delineation of the pathogenetic pathways that they influence, holds promise for the development of new therapeutic strategies. The current data suggest probable benefit for therapeutic targeting of neutrophils in this devastating disease. These data also suggest that the IFRD1/HDAC axis may provide a tractable therapeutic target in CF, and other diseases in which neutrophils have an important pathogenetic role.
METHODS SUMMARY
Genetic analysis. CF patients were from the GMSG 5 and CFTSS 1 cohorts. Healthy controls were recruited at CCHMC. Studies were approved by the relevant Institutional Review Boards. Genome-wide analysis was performed using Affymetrix GeneChip 100K Human Mapping microarrays. Other genotyping was performed using Taqman PCR, AcycloPrime-FP SNP PCR, Illumina 610 Quad chips and llumina SNP beadarray genotyping. Follow-up association analysis (GMSG cohort) was performed using SNPGWA 22 . Association and transmission analysis (CFTSS cohort) was done using PEDSTATS v.0.6.6 (http://www.sph. umich.edu/csg/abecasis/Pedstats) 23 , Intercooled Stata 8, quantitative transmission disequilibrium testing (QTDT) v.2.5.0 (http://www.sph.umich.edu/csg/abecasis/ QTDT) 24 , and Golden Helix software (http://www.goldenhelix.com). Quantitative trait analysis (healthy donor cohort) was performed using PLINK version 1.03 (http://pngu.mgh.harvard.edu/,purcell/plink/). Cellular assays. Surface and intracellular FACS staining was performed as described 25 . Quantification of mRNA was performed by qRT-PCR, as described 25 . Oxidative burst capacity was quantified by flow cytometry using the dihydrorhodamine 123 assay 26 . TNF-a production was quantified by ELISA (BD Pharmingen) or by intracellular staining, as described 27 . LTB 4 production was quantified by ELISA (Neogen). Bacterial killing was quantified as described 28 . Neutrophil chemotaxis was quantified as described 29 . Nuclear NF-kB p65 DNA-binding activity was quantified using the EZ-Detect Transcription Factor ELISA (Pierce). Co-immunoprecipitation of nuclear proteins was performed using the Nuclear Complex Co-IP kit from Active Motif. Mouse models. Mice were non-traumatically challenged intratracheally with P. aeruginosa (FRD1 strain). Forty-eight hours later, mice were euthanized. BAL cell analysis, lung bacterial burden and myeloperoxidase activity were quantified as described 4 . BAL and serum cytokines were quantified by ELISA (BD Pharmingen, R&D) or by the Cincinnati capture assay 30 . Standard bone marrow cell transfer techniques were used. Suberoylanilide hydroxamic acid (SAHA), from Cayman, was administered intraperitoneally. Mice were non-traumatically challenged intratracheally with P. aeruginosa LPS (Sigma). Animal care was provided in accordance with National Institutes of Health guidelines. Studies were approved by the CCHMC Institutional Animal Care and Use Committee.
